RxDoctor Payments DataLook up a doctor →

Jason Ricci, MD

Interventional Cardiology · Petoskey, MINPI 1750596466

Payments from drug & device makers

$1,137,287in general payments, 2019–2025

Across 500 payments — averaging $2274.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1M
  • Surmodics, Inc.$50K
  • Edwards Lifesciences$45K
  • Endologix LLC$7K
  • Medtronic$2K
  • Bard Peripheral Vascular, Inc.$875
  • plus $1K from 11 others
$12,025in research payments, 2019–2025

Across 2 payments — averaging $6012.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$12K

What the payments were for

  • Consulting fees$67,39911%
  • Speaking & faculty fees$285,77348%
  • Travel & lodging$233,00339%
  • Food & beverage$7,7501%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,137,287 in reported general payments places this provider in the 95th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$121,454
Medicare patients
489
Services billed
874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban109$120,014
XareltoRivaroxaban34$36,809
JardianceEmpagliflozin23$26,698
WegovySemaglutide11$14,362
EntrestoSacubitril/Valsartan16$13,275
Repatha SureclickEvolocumab21$11,728
Atorvastatin Calcium145$1,505
Metoprolol Succinate107$1,440
ClopidogrelClopidogrel Bisulfate138$1,252
Rosuvastatin Calcium92$1,125
Prasugrel Hcl16$1,036
Losartan Potassium121$1,015
Ezetimibe26$866
Carvedilol45$621
Bumetanide15$410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$103$120,014109 claims
NovartisEntresto$93$13,27516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Petoskey

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →